Acute Kidney Injury News

BOSTON — For deceased donor transplants, AKI in the donor did not have any negative impact on eGFR in the recipient at 1 year, according to a poster presented at the American Transplant Congress.

Researchers found patients who were diagnosed with acute interstitial nephritis had higher levels of urinary TNF-alpha and interleukin-9, which suggests that testing these levels could improve clinical diagnosis, according to a published study.

BOSTON — Disparities in which women are more likely to develop pregnancy-related AKI, often thought of in terms of genetics and race, may instead be primarily due to socioeconomic factors that result in unequal access to health care, according to a poster presented at the National Kidney Foundation Spring Clinical Meetings.

A published review outlined drug-induced nephrotoxicity, a common cause of acute kidney injury, and its associated factors surrounding medications, drugs and other ingested substances.

Proton pump inhibitor use was associated with increased risks for acute kidney injury and chronic kidney disease, according to a published study.

When introduced to hospitals in the United Kingdom, a multifaceted intervention designed to reduce avoidable harm associated with acute kidney injury improved delivery of care, which subsequently led to better outcomes for patients with AKI, according to a study published in the Journal of the American Society of Nephrology.

Patients with lupus demonstrate characteristic gut microbiome dysbiosis patterns, which appear to directly correspond to disease activity, according to data published in the Annals of the Rheumatic Diseases.

The risk for acute kidney injury may be reduced if vancomycin area under the curve dosing measured within the first or second 24 hours is lower than approximately 650 mg*h/L, according findings from a systematic review and meta-analysis.

An analysis of 9,000 patients with diagnosed acute kidney injury treated at Fresenius Medical Care North America outpatient clinics indicates that about one-third of patients will recover kidney function within 90 days of starting in-center hemodialysis and one in six with persistent AKI will recover kidney function by 150 days. Overall, 38% of patients recovered kidney function within 150 days of initiating outpatient therapy, the company said in a press release.

The risk for developing AKI and hypocalcemia may be higher for patients treated with PD-1 inhibitors than those treated with non-nephrotoxic agents, according to a recently published study.